NWPF

News ArchivesRead News

New Digital Cognitive Assessment Tool Receives Positive FDA Review

Monday July 31, 2017

Carolina Henriques

Parkinson's News Today - The cognitive science company Cogstate received approval to market a new digital cognitive assessment tool to assist healthcare professionals in measuring cognition in patients ages 6 to 99, either in-clinic or at home. This tool, called the Cognigram, could help measure the progression of Parkinson’s disease and other illnesses.

The Cognigram can now be marketed in the United States after the U.S. Food and Drug Administration (FDA) reviewed the company’s 510(k) submission and found it to meet the necessary requirements established by the FDA’s Center for Devices and Radiological Health.

An individual’s cognition may be affected by mild cognitive impairment (MCI), Alzheimer’s disease, Parkinson’s disease, concussion, head injury, HIV-related dementia, major depressive disorder, and secondary effects of medication or surgery, among others, including psychological states like stress or fatigue.

The Cognigram system is a simple computerized battery of tests based on a card game designed to detect and monitor change in cognitive function over time. The system can be used to assess cognition on a single occasion or cognitive change over periodic assessments, regardless of language, education, and cultural background.

The Cognigram will be made available to U.S. health systems, hospitals, physician practices, elderly care organizations, schools, and sports teams.

“After more than fifteen years of intense efforts in supporting academic research and pharmaceutical clinical trials around the world, Cogstate is excited to enter the U.S. market for cognitive assessment on the front lines of clinical practice,” Frank Cheng, president of Cogstate Healthcare, said in a press release. “We look forward to bringing the proven and widely-published Cognigram technology into the healthcare ecosystem to benefit an exponentially larger pool of patients.”

A 2015 study explored controversies about mild cognitive impairment in Parkinson’s disease (PD-MCI), noting that cognitive impairment in Parkinson’s is increasing.

MCI is a known risk factor for dementia in Parkinson’s, but this process isn’t fully understood. In this study, the authors explored signs of PD-MCI, biomarkers, and how PD-MCI factors into clinical trial design.

The article also explores how PD-MCI definitions have evolved over the years, and how prevention may be incorporated into PD treatment. Today, monitoring PD-MCI is commonly incorporated as a measurement for PD clinical trials.

Titled, “Mild cognitive impairment: an update in Parkinson’s disease and lessons learned from Alzheimer’s disease,” the article was published in Neurodegenerative Disease Management.

https://parkinsonsnewstoday.com/2017/07/31/parkinsons-disease-cognitive-assessment-tool-cognigram-receives-positive-fda-notification-for-us-marketing/

Recent News

Oct 18 - Fighting Parkinson's disease through dance
Oct 18 - Brain disconnections may contribute to Parkinson's hallucinations
Oct 17 - Scientists Identify Structure of PINK1, Key Parkinson’s-protective Protein
Oct 17 - Diabetes drug cuts Parkinson's risk by 28 percent, study finds
Oct 10 - Advances in Brain Pacemaker Reduces Tremors, Helps Parkinson's Sufferers Live a More Normal Life
Oct 10 - Medical History Could Help Predict Parkinson's Disease Risk Long Before Diagnosis
Oct 3 - Changes in Olfactory Bulb Explain Loss of Smell in Early Stages of Parkinson’s Disease, Study Finds
Oct 3 - Sleep Disturbances May Worsen Motor Symptoms in Parkinson’s Disease, Study Suggests
Sep 12 - Australian Researchers Develop New Diagnostic Tool to Spot Early Signs of Parkinson’s
Sep 11 - GeneFo Webinar to Focus on Using Humor to Manage Parkinson’s Disease
Sep 6 - Parkinson’s and the ‘D’ word
Sep 6 - Compounds in Asthma Drugs Might Be Used as Parkinson’s Treatment
Sep 5 - AstraZeneca Joins Takeda, Berg to Advance Development of Parkinson’s Disease Therapies
Sep 1 - Stem Cell Transplant Trial in Parkinson’s Patients Planned After Test in Japan Succeeds in Monkeys
Sep 1 - Titan to Start Phase 1/2 Study of Subdermal Implant to Deliver Requip to Parkinson’s Patients
Aug 30 - FDA Refuses Acorda’s Inbrija New Drug Application Due to Manufacturing Questions
Aug 23 - Support Groups: Are They for You?
Aug 22 - Internet Visits with Parkinson’s Specialist Can Be as Effective as In-person Visits, Trial Finds
Aug 21 - Cavion’s New CMO to Lead Cav3 Platform Development for Neurological Diseases
Aug 15 - Singing Helps Early-stage Parkinson’s Patients Retain Speech, Respiratory Control, Studies Show